Description

ITRALASE 100 MG (1X15)

Indications

ITRALASE 100 MG is primarily indicated for the treatment of various fungal infections, particularly those caused by susceptible strains of dermatophytes, yeasts, and molds. It is effective in managing conditions such as onychomycosis, tinea pedis, tinea corporis, and candidiasis. The drug is prescribed for patients who have shown resistance to other antifungal therapies or when rapid fungal eradication is necessary.

Mechanism of Action

ITRALASE contains the active ingredient Itraconazole, which belongs to the class of triazole antifungals. Its mechanism of action involves the inhibition of fungal cytochrome P450-dependent enzyme 14α-demethylase. This enzyme is crucial for the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. By disrupting ergosterol synthesis, Itraconazole alters the cell membrane’s integrity, leading to increased permeability and ultimately resulting in cell death. This action is effective against a broad spectrum of fungi, making ITRALASE a versatile choice in antifungal therapy.

Pharmacological Properties

ITRALASE is characterized by its pharmacokinetic properties that enhance its efficacy in treating fungal infections. After oral administration, Itraconazole is rapidly absorbed, with peak plasma concentrations typically reached within 2 to 5 hours. The bioavailability of Itraconazole is significantly increased when taken with food, particularly high-fat meals, which is an important consideration for dosing. The drug is extensively metabolized in the liver, with a half-life of approximately 24 hours, allowing for once-daily dosing in many cases. Itraconazole is primarily excreted through the feces, with only a small percentage eliminated via urine.

Contraindications

ITRALASE is contraindicated in patients with known hypersensitivity to Itraconazole or any of its components. It should not be used in individuals with a history of heart failure or other significant cardiac conditions, as it may exacerbate these conditions. Additionally, the use of ITRALASE is contraindicated in patients who are concurrently taking certain medications, such as cisapride, pimozide, and certain ergot alkaloids, due to the risk of severe drug interactions.

Side Effects

Like all medications, ITRALASE may cause side effects, although not everyone experiences them. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Other reported side effects may include headache, dizziness, and rash. Serious adverse effects, though rare, can occur, including hepatotoxicity, heart failure, and severe allergic reactions. Patients are advised to report any unusual symptoms to their healthcare provider promptly to ensure appropriate management.

Dosage and Administration

The recommended dosage of ITRALASE for adults varies depending on the type and severity of the fungal infection being treated. For onychomycosis, a common regimen is 200 mg once daily for 12 weeks. For other fungal infections, the dosage may range from 100 mg to 200 mg daily, depending on the clinical scenario. It is essential to follow the prescribing physician’s instructions and complete the full course of therapy, even if symptoms improve before the treatment is finished. ITRALASE should be taken with food to enhance absorption and effectiveness.

Interactions

ITRALASE has the potential to interact with several medications, which may alter its effectiveness or increase the risk of adverse effects. Notable interactions include those with anticoagulants, such as warfarin, which may require careful monitoring of INR levels. Additionally, concurrent use with certain antiepileptic drugs, statins, and immunosuppressants may necessitate dosage adjustments. It is crucial for patients to inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before initiating therapy with ITRALASE, a thorough medical history should be obtained, particularly regarding any cardiovascular issues, liver disease, or history of allergic reactions. Regular monitoring of liver function tests is recommended during treatment, especially in patients with pre-existing liver conditions. Caution should also be exercised in elderly patients and those with renal impairment, as they may be more susceptible to adverse effects. Pregnant or breastfeeding women should only use ITRALASE if the benefits outweigh the risks, and under the guidance of a healthcare professional.

Clinical Studies

Clinical studies have demonstrated the efficacy of ITRALASE in treating various fungal infections. In a randomized controlled trial involving patients with onychomycosis, Itraconazole showed a significantly higher mycological cure rate compared to placebo. Another study focused on the treatment of tinea pedis highlighted the rapid onset of action and sustained efficacy of ITRALASE, with a notable reduction in symptoms and fungal burden. These studies underscore the importance of ITRALASE as a first-line treatment option in managing fungal infections effectively.

Conclusion

ITRALASE 100 MG is a potent antifungal agent that plays a crucial role in the management of various fungal infections. Its unique mechanism of action, combined with favorable pharmacokinetic properties, makes it an effective choice for patients requiring antifungal therapy. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Proper dosage and adherence to the prescribed regimen are vital for achieving optimal therapeutic outcomes. As with any medication, a comprehensive discussion with a healthcare provider is recommended to ensure safe and effective use of ITRALASE.